Cardiovascular disease (CVD) places a major health and economic burden on society. Early detection is critical for effective treatment and improved outcomes of CVD. Cardiatec Ltd. has developed Endotect, a breakthrough, non-invasive, easy-to-use medical device for accurate early detection of CVD risk. Cardiatec's Endotect is poised to reduce substantially the threat of cardiovascular disease and the cost of its treatment. |
Cardiatec's device, the Endotect, is a breakthrough in ED measurement technology. Endotect determines ED through analysis of blood flow in the brachial/radial arteries of the arm, not at the fingertip as in other technologies, thus offering both simplicity as well as a high level of accuracy in the assessment of ED. The Endotect's accuracy is not impacted by ambient factors.
|
Cardiatec Ltd. is a medical device company at the forefront of cardiovascular disease research |
